Background: The purpose of this study was to determine the feasibility and tolerability of tandem courses of high-dose thiotepa with autologous hematopoietic cell rescue (AHCR) in patients with recurrent, refractory solid tumors who were ineligible for a single course of high-dose therapy due to greater than minimal residual disease. Patients with decreased hearing or poor renal function were eligible. Procedure: Thiotepa was administered intravenously at a dose of 200 mg/m 2 /day (6.67 mg/kg/day) daily for 3 days followed by AHCR. A second course of thiotepa was given 4 weeks later provided blood counts recovered sufficiently without evidence of tumor progression. Results: Fifty-eight patients received 96 courses. Thirty-eight (65%) patients received two courses of therapy. Twenty-seven courses (28%) were administered completely in the outpatient setting. A toxic mortality rate of 3.4% was observed. Five of 26 patients with medulloblastoma were alive at a median of 35 months, whereas 21 patients died at a median of 11.7 months. Four of five patients with central nervous system germ cell tumors (CNS GCT) were alive 68-103 months following AHCR. Conclusions: Two cycles of high-dose thiotepa with AHCR were well tolerated even in these heavily pretreated patients. This therapy may provide prolonged survival in patients with recurrent malignant brain tumors, particularly medulloblastoma and CNS GCT.
INTRODUCTION
The prognosis for children, adolescents, and young adults with recurrent or refractory malignant solid tumors remains poor. Many studies have reported on the efficacy of myeloablative chemotherapy with autologous hematopoietic stem cell rescue (bone marrow or peripheral blood) for patients, predominantly using a single cycle of myeloablative therapy. [1] [2] [3] [4] [5] [6] There are some encouraging data utilizing this approach for patients with central nervous system (CNS) tumors such as medulloblastoma and primary CNS germ cell tumors (GCT), [7] [8] [9] neuroblastoma, 10, 11 and Wilms tumor. 12, 13 Most studies report that if Abbreviations: AHCR, autologous hematopoietic cell rescue; ANC, absolute neutrophil count; CNS, central nervous system; CR, complete response; CSF, cerebrospinal fluid; CSI, craniospinal Irradiation; GCT, germ cell tumors; NR, no response; PD, progressive disease; PR, partial response benefits are seen, they are in patients with minimal residual disease and good organ function.
Unfortunately many patients are unable to achieve a state of minimal residual disease despite the use of chemotherapy, irradiation, and/or surgery following tumor recurrence. In addition, these patients often have toxicity from prior therapy, rendering them poor candidates for high-dose chemotherapy regimens incorporating multiple drugs.
The primary goal of the current study was to determine the feasibility and toxicity of administering two consecutive myeloablative courses of thiotepa each with autologous hematopoietic cell rescue (AHCR) in a multicenter trial for children, adolescents, and young adults with recurrent/refractory solid tumors who were not eligible for a single myeloablative multidrug regimen due to residual disease.
In addition, we report data on the tumor response to this tandem regimen.
Patients with tumors involving the bone marrow had to be free of disease in the marrow at the time of hematopoietic cell harvesting, proven by morphologic and cytogenetic evaluations. Adequate organ function was measured by the following: bilirubin less than or equal to 1.5× the upper limit of normal, ALT and AST less than or equal to 2.5× the upper limit of normal unless the liver was involved with tumor; serum creatinine within the normal range or, if the serum creatinine was outside the normal range, then patients were required to have a creatinine clearance greater than or equal to 70 ml/min/1.73 m 2 ; a fractional shortening greater than 28% or ejection fraction greater than 55% on echocardiogram prior to the first course of thiotepa; asymptomatic for pulmonary disease or, if symptomatic, the patient had to have a diffusion capacity greater than 50% of predicted (corrected for hemoglobin). Pregnant or lactating women were excluded.
Patients did not receive concurrent radiotherapy and/or chemotherapy. Corticosteroids were permitted for their antiedema effects and were not used solely as an antiemetic.
Treatment
Thiotepa was administered as a 3-hr daily infusion for three consecutive days at a dose of 200 mg/m 2 /day, equivalent to 600 mg/m 2 /course for those patients weighing more than 25 kg. For patients weighing 25 kg or less, thiotepa was dosed as 6.67 mg/kg, equivalent to 20 mg/kg/course. A second course of thiotepa was administered at least 4 weeks following the initiation of the first course in patients with responsive or stable disease, an ANC ≥ 1,000/ l without growth factor and when the patient was no longer platelet transfusion dependent. All patients were intended to undergo two courses of thiotepa. 
Toxicity
Toxicity data were obtained from the patients' medical records and graded in accordance with Common Toxicity Criteria from the National Institutes of Health, United States, version 1 (1988-1998) and version 2 (1999-2006) . The data toxicity grades of interest were those ≥ grade III; because grades I and II toxicities were considered acceptable given the lack of treatment alternatives for this patient population at that time.
Supportive measures
Patients received supportive care including antiemetics, as well as blood product transfusions as needed to maintain adequate hematologic parameters. Febrile neutropenia was treated with standard intravenous antibiotic therapy, and antifungal treatment was administered as per the institutional guidelines. Prophylaxis for pneumocystis pneumonia and herpes virus was provided as per institutional preference.
Required observations
Blood work including complete blood count, comprehensive chemistry profile, and creatinine clearance was performed prior to each course of thiotepa. Pulmonary function tests were obtained prior to each course in patients who were symptomatic. Tumor response was assessed radiographically and, if indicated by CSF cytology and/or serum and CSF tumor markers, prior to each course of thiotepa and every 3 months for 1 year following the last course of thiotepa or until there was evidence of progressive/recurrent disease. 
Disease response criteria

Response rate
Response to therapy was defined as follows: (1) 
RESULTS
Between September 1997 through September 2002, 58 patients with a variety of recurrent, refractory, poor prognosis malignancies diagnosed between ages 0.1 and 40.1 years old (median: 7.7 years old) were enrolled (see Table 1 ). All patients had recurrent, refractory of progressive tumor following standard treatment approaches for their disease, the majority having received a combination of surgery, chemotherapy, and radiation therapy as further described in Table 1 . Thirty-six patients (62%) had metastatic disease prior to initiating their first course of thiotepa.
Of the 58 patients who underwent their first course of thiotepa, one patient experienced grade III hepatic toxicity attributed to thiotepa.
Two patients experienced CNS-general grade IV events that were transient, characterized by altered mental status, and possibly attributable to thiotepa. One of these events occurred shortly after the AHCR. The etiology remained unclear and the patient's electroencephalogram did not reveal any seizure activity. Another patient was admitted for a grade 3 infection, fever, and bacteremia with Stenotrophomonas maltophilia. His catheter was removed and he was treated with IV antibiotics with full recovery (Table 2 ).
There were two toxic deaths experienced in this protocol. The first patient was a 5-year-old male child with an incompletely resected medulloblastoma treated with chemotherapy followed by craniospinal irradiation (CSI), which was administered 6 months prior to being enrolled on to our study. He never engrafted and died 3 months after his first course. The cell dose administered for this patient was 2.5 × 10 6 CD34+ cells/kg. Of note, there were 12 other patients who received CSI prior to AHCR; 10 of which successfully underwent two 
TA B L E 2 Patient characteristics and postthiotepa attributable toxicities
Not evaluable 4 PR1 = 2, PD = 2 CR, complete response; PR, partial response; NR, no response or stable disease; PD, progressive disease.
gastrointestinal toxicity), 44 days (grade IV neurotoxicity), and 50 days (grade III respiratory toxicity) interval days between courses 1 and 2. We did not find there was a correlation with toxicity and interval between first and second thiotepa courses.
Days of hospital stay ranged from 0 to 34 days in the first course (median: 6 days) and 0-54 days in the second course (median: 4 days) ( Table 2 ). The number of patients with zero days of hospitalization received treatment solely as an outpatient: 13 patients (22%) never required hospitalization during the first thiotepa course and nine patients (23%) never required hospitalization during the second thiotepa course ( Table 2 ). The median days to ANC engraftment for the first course was 11 days (range: 7-78 days) and 11 days for the second course (range: 7-51 days). Two patients did not engraft during the first course, one of whom engrafted after the second course.
Intravenous antibiotics were utilized in 40 (72%, n = 55) patients in the first course and in 23 (61%, n = 38) patients in the second course.
Intravenous amphotericin was administered to five (9%) patients in the first course and to five (11%) patients in the second course. Morphine (Table 3) .
Best response to therapy was measured as described in the Methods section and was evaluable in 54 of 58 patients after the first cycle and in 20 of 38 patients after the second cycle. Five patients achieved a CR, 12 had a PR, 22 had NR or stable disease, and 15 had PD (Table 4 ).
The various disease statuses at study entry are also detailed in Table 4 .
Of the 12 long-term survivors, seven were reported to be without evidence of disease in follow-up for 2-5.8 years (median 3.6 years).
Five additional patients were reported as long-term survivors with disease 1.4-3.2 years (median 2 years) from thiotepa administration.
Patients with recurrent CNS GCT (n = 5) composed the largest number of survivors free of disease: four with no evidence of disease 3-5 years following thiotepa and one lost to follow-up after completing one cycle of treatment. Two of 18 patients with medulloblastoma had no evidence of disease at 2 and 6 years from thiotepa therapy, five patients were alive with disease at 1-3 years from thiotepa, and two patients experienced toxic deaths during the first cycle of thiotepa. The remaining 44 patients died of tumor progression (Table 5) .
Data regarding treatments offered to survivors after the study were not captured since the main focus of our study was safety, feasibility, and tolerability of this regimen. Patients were not routinely offered or placed on any posttransplantation maintenance regimens and our study was not powered to analyze survival outcomes.
DISCUSSION
Thiotepa is a polyfunctional alkylating agent that has been used in clinical trials since the 1950s. 5, [14] [15] [16] These early studies demonstrated that thiotepa had activity against a wide variety of neoplasms;
however, thiotepa was not widely used because of its association with severe myelosuppression even at modest doses. Over the years, The major goal of our study was to determine the tolerability of two sequential courses of thiotepa, each with AHCR. Patients with recurrent or refractory poor prognosis malignancies were eligible to participate, thereby selecting for a patient population that had received and failed standard treatment for their disease. In this prospective study, we observed that tandem courses of thiotepa were generally well tolerated in an already heavily pretreated and poor prognostic patient population several of which received CSI. After it was deemed to be safe the goal would be for it to become the backbone for a transplant regimen in combination with other drugs.
The toxic mortality rate of 3.4% with this tandem regimen was clearly reduced in comparison to reported mortalities with single course regimens like that reported by Nazemi et al. from a pilot study for CNS embryonal tumors in CCG99702 that preceded AHCR with CSI in newly diagnosed patients. 23 Other comparable studies utilizing high-dose chemotherapy and AHCR predominate in infants and young children, who tolerate high doses of chemotherapy and AHCR better than older children and adults present in our study. Additionally, nonhematologic toxicities with this tandem thiotepa regimen were less than those seen with single-course multidrug regimens. There were no reports of either ototoxicity or nephrotoxicity in these patients.
Favorable responses with durable outcomes were noted in the patients with recurrent CNS germ cell tumors and, to a lesser degree, in patients with recurrent medulloblastoma, in keeping with prior reports. 6, 20 The small population size precludes us from drawing definitive conclusions regarding survival outcomes for individual malignancies. Nevertheless, it is apparent that in our heavily pretreated population, tandem thiotepa is a tolerable regimen where one-fourth of patients are able to receive their treatment entirely in the outpatient setting. The findings of our study merit further investigation into the use of tandem thiotepa in patients with CNS malignancies, given its tolerability and excellent CSF penetration. This approach may best be used in combination with other therapies such as molecularly targeted drugs or immunotherapy that work best in the setting of minimal residual disease.
